Clinical Trial

The Safety and Efficacy of XytriX (Umbilical Cord-Derived Mesenchymal Stem Cells) in the Treatment of Knee Osteoarthritis

Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This study aims to study the safety and efficacy of XytriX, an umbilical cord-derived stem cell product, in the treatment of Grade I-IV knee osteoarthritis.
Protocol Amendment History 3 changes
notable Enrollment increased: 50 -> 75 participants 2026-04-14
minor Trial arms changed: 1 -> 3 2026-04-14
minor Completion pushed: 2027-12 -> 2028-12 2026-04-14
Trial Details
NCT Number NCT07487766
Lead Sponsor TricelX Inc.
Conditions Osteoarthritis
Enrollment 75 participants
Start Date 2026-05
Primary Completion 2027-05 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-04-13